Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.540NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.540NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.540NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.540NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.540NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.540ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.487ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.487ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.487NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.487NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.487NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.487NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.487NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.487ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.1.118ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.1.118ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.1.118NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
B.1.1.118NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.1.118NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.1.118NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.1.118NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.310ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.310NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.310NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.310NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.310NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.310NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.310ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.1.185ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.1.185ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.1.185NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
B.1.1.185NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.1.185NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.1.185NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.1.185NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.1.185ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.258.9ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.258.9ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.258.9NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.258.9NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.258.9NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.258.9NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
B.1.258.9NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
B.1.258.9ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.329ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
B.1.329ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.329NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-22844.7China
B.1.329NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.329NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.329NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used